LifeVantage (NASDAQ:LFVN) Shares Cross Above 200-Day Moving Average – Here’s What Happened

LifeVantage Co. (NASDAQ:LFVN)’s share price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $15.57 and traded as high as $17.64. LifeVantage shares last traded at $17.04, with a volume of 153,399 shares changing hands.

Analyst Ratings Changes

LFVN has been the subject of a number of research analyst reports. Lake Street Capital started coverage on shares of LifeVantage in a research report on Thursday, December 19th. They issued a “buy” rating and a $26.00 target price for the company. Craig Hallum began coverage on LifeVantage in a research note on Tuesday, January 14th. They issued a “buy” rating and a $35.00 price target on the stock.

LifeVantage Stock Performance

The company’s 50-day moving average price is $19.80 and its 200 day moving average price is $15.63. The stock has a market cap of $204.33 million, a PE ratio of 29.07 and a beta of 0.74.

LifeVantage (NASDAQ:LFVN) last announced its earnings results on Wednesday, February 5th. The company reported $0.22 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.08. LifeVantage had a net margin of 3.46% and a return on equity of 34.29%.

LifeVantage Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, March 17th. Investors of record on Monday, March 3rd were given a dividend of $0.04 per share. The ex-dividend date of this dividend was Monday, March 3rd. This represents a $0.16 annualized dividend and a yield of 0.98%. LifeVantage’s dividend payout ratio (DPR) is presently 28.57%.

Insider Buying and Selling at LifeVantage

In other news, Director Raymond B. Greer sold 8,000 shares of the firm’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $20.15, for a total value of $161,200.00. Following the transaction, the director now owns 99,288 shares of the company’s stock, valued at $2,000,653.20. This trade represents a 7.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 20.65% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On LifeVantage

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. LPL Financial LLC lifted its holdings in LifeVantage by 301.0% during the fourth quarter. LPL Financial LLC now owns 211,039 shares of the company’s stock valued at $3,700,000 after purchasing an additional 158,405 shares in the last quarter. Ancora Advisors LLC bought a new stake in shares of LifeVantage during the 4th quarter valued at $1,138,000. EAM Investors LLC purchased a new position in shares of LifeVantage during the 4th quarter valued at $1,056,000. Susquehanna International Group LLP lifted its stake in shares of LifeVantage by 83.5% during the 4th quarter. Susquehanna International Group LLP now owns 128,082 shares of the company’s stock valued at $2,245,000 after buying an additional 58,279 shares in the last quarter. Finally, HighTower Advisors LLC bought a new position in LifeVantage in the 3rd quarter worth $638,000. 35.32% of the stock is owned by hedge funds and other institutional investors.

About LifeVantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.